Skip to main content

United States News All stories

Every story in this section, newest first — page 351 of 373.

Grafa
Technology

Matthews International finalizes $232M warehouse unit sale to Duravant

Matthews International Corporation (NASDAQ:MATW) officially closed the sale of its Warehouse Automation business to Duravant on Wednesday, December 31, 2025.

The deal, first announced in mid-November, provides the Pittsburgh-based firm with $232.1 million in total consideration, including $225.4 million in cash.

Read more: Matthews International finalizes $232M warehouse unit sale to Duravant
Grafa
Health

FibroBiologics files for first human trial of novel psoriasis therapy

FibroBiologics (NASDAQ:FBLG) took a decisive step toward clinical-stage operations on Wednesday, filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to begin Phase 1/2 trials for its lead psoriasis candidate, CYPS317.

Read more: FibroBiologics files for first human trial of novel psoriasis therapy
Grafa
Technology

SOL strategies revenue climbs 37% as Solana treasury hits CAD$126 million

SOL Strategies (NASDAQ: STKE) reported full-year financial results for the fiscal year ended September 30, 2025, posting revenue of CAD$14.5 million, a 36.7% increase year over year, driven primarily by the expansion of its staking and validator operations within the Solana ecosystem.

Read more: SOL strategies revenue climbs 37% as Solana treasury hits CAD$126 million
Grafa
Technology

Taylor Devices hits record Q2 sales as defense orders offset industrial headwinds

Taylor Devices (NASDAQ:TAYD) reported record-breaking financial results for the second quarter of fiscal 2026, as the North Tonawanda-based manufacturer leveraged strong demand from the aerospace and defense sectors to overcome broader economic pressures in its structural and industrial markets.

Read more: Taylor Devices hits record Q2 sales as defense orders offset industrial headwinds
Grafa
Health

Axsome jumps as FDA grants priority review for Alzheimer’s agitation drug

Axsome Therapeutics (NASDAQ:AXSM) shares edged higher Wednesday after the U.S. Food and Drug Administration (FDA) granted Priority Review to its supplemental New Drug Application (sNDA) for AXS-05, a treatment targeting the pervasive and distressing agitation associated with Alzheimer’s disease.

Read more: Axsome jumps as FDA grants priority review for Alzheimer’s agitation drug